The company presented data during the American Society for Microbiology Biodefense and Emerging Diseases Research meeting in Washington, D.C. Initial animal models indicated that their obiltoxaximab, an anti-toxin that they have developed to combat anthrax spores, could have potential as study animals that received the compound positively countered different amounts and concentrations of infectious material.
In a second presentation, they explained the compound was especially effective when it was injected into the muscular system. In the studies, those who received the injection showed that anthrax spores were unable to develop protective antigen toxemia and bacteremia.
“Elusys is pleased to be presenting important data on the efficacy and pharmacology of obiltoxaximab,” Elusys President and CEO Elizabeth Posillico said. “We have completed the nonclinical efficacy studies required for filing our biologics license application and are delighted and confident that our BLA will be submitted in the coming weeks. We believe that obiltoxaximab can be an important addition to the Strategic National Stockpile to help protect the U.S. public from this deadly bioterror threat.”
According to the announcement, this compound is the only antitoxin against anthrax in the advanced stages of development.